CurrentUnitedHealthcarePolicy CS021NE.Q

Collagen Crosslinks and Biochemical Markers of Bone Turnover (for Nebraska Only)

UnitedHealthcare medical policy applicable only to Nebraska that addresses coverage and medical necessity of serum or urine collagen crosslinks and biochemical markers of bone turnover for assessing fracture risk, predicting bone loss, or monitoring response to antiresorptive therapy.

Policy Summary

PayerUnitedHealthcare

PolicyCollagen Crosslinks and Biochemical Markers of Bone Turnover (for Nebraska Only)

Policy CodePolicy CS021NE.Q

Change TypeSupporting information updated

Effective DateFeb 1, 2026

Next Review Date

Key ActionClaims for serum or urine collagen crosslinks or biochemical markers to assess fracture risk, predict bone loss, or assess response to antiresorptive therapy are considered unproven and not medically necessary and are subject to denial.

POLICY UPDATE CHANGES

02/01/2026 Summary of Changes = Supporting Information: Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

1Referenced CPT codes

NebraskaGeographic scope

Not medically necessaryCoverage stance

Multiple societiesGuideline Coverage

Updated

Coverage Summary

UnitedHealthcare medical policy CS021NE.Q applicable only to Nebraska (Effective February 1, 2026) addresses coverage of serum or urine collagen crosslinks and biochemical markers of bone turnover (BTMs). The policy evaluates these tests when used to assess fracture risk, predict bone loss, or monitor response to antiresorptive therapy and states that these services are unproven and not medically necessary for those indications.

Policy scope & stance

Geographic scopeNebraska only (policy applies only to the State of Nebraska)

Coverage stanceNot medically necessary (Serum or urine collagen crosslinks or biochemical markers are unproven and not medically necessary to assess fracture risk, predict bone loss, or assess response to therapy)

Policy effective dateFebruary 1, 2026

Policy numberCS021NE.Q

Guideline Coverage noteGuideline summaries from multiple societies included (ESCEO/IOF/IFCC, Endocrine Society, ISCD, BHOF, NAMS, Osteoporosis Canada) — markers have potential roles but limitations and need for standardization noted

Medical-Necessity Criteria

Coverage Rationale / Medical Necessity

Covered when ALL of the following are met:

ALL of the following

Service is serum or urine collagen crosslinks or biochemical markers of bone turnover
policy applies only to Nebraska
Use to assess risk of fracture, predict bone loss, or assess response to antiresorptive therapy
These indications are specifically evaluated by the policy
Clinical evidence supports medical necessity
Policy determination: clinical validity is unproven and evidence insufficient

Not Medically Necessary

Coding

Referenced CPT codesCPT

82523

Collagen cross links, any method

Provider Actions

Denial Risk

Not medically necessary — collagen crosslinks / BTMs

Claims for serum or urine collagen crosslinks or biochemical markers of bone turnover to assess fracture risk, predict bone loss, or assess response to antiresorptive therapy are considered unproven and not medically necessary and are subject to denial.

82523

Documentation Required

Use policy in benefit determinations

When deciding coverage, reference federal, state or contractual benefit plan requirements which may differ from this standard policy; in event of conflict, contractual requirements govern.

Background & Evidence

Biochemical bone turnover markers (formation and resorption markers such as P1NP, CTX, osteocalcin, NTx and others) are measurable in serum or urine and are available commercially using methods like high-performance liquid chromatography or immunoassay. They have been used in research to assess bone remodeling, fracture risk, and treatment response. However, clinical use is limited by preanalytical and analytical variability (diurnal variation, feeding status, assay differences), a lack of standardization across laboratories and assays, and insufficient prospective, well-designed evidence to establish clinical validity for diagnosing osteoporosis, predicting fractures, or reliably monitoring therapy response.

Evidence Element	Summary
Overall evidence summary
Clinical validity unproven; insufficient evidence to support diagnosis of osteoporosis or monitoring response to treatment; prospective well-designed trials needed.
Policy coverage stance
Serum or urine collagen crosslinks or BTMs are considered unproven and not medically necessary to assess fracture risk, predict bone loss, or assess response to antiresorptive therapy (Nebraska-only).
Description / limitations
BTMs measure formation (e.g., P1NP, osteocalcin, BALP) and resorption (e.g., CTX, NTx, pyridinoline); use in clinical practice is limited by biological and analytical variability and lack of standardization across labs.
Guideline positions
Guidelines vary: ESCEO/IOF/IFCC (2025) reaffirm PINP and β-CTX-I as reference BTMs; some societies recognize potential roles for PINP and CTX for monitoring or risk assessment but note limitations and need for standardization (AACE/ACE, BHOF, Endocrine Society, ISCD, NAMS, Osteoporosis Canada).

BTMs: Biochemical markers of bone turnover, including formation markers (e.g., P1NP, osteocalcin, bone alkaline phosphatase) and resorption markers (e.g., CTX, NTx, pyridinoline), measured in serum or urine.

PINP / β-CTX-I: Serum PINP and plasma β-CTX-I have been re-affirmed by international consensus groups as reference BTMs for osteoporosis monitoring when standardized assays are used.

Revision History

02/01/2026revisedLatest

02/01/2026 Summary of Changes = Supporting Information: Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.